Skip to main content
logo
Amicus Therapeutics, Inc. (FOLD)
Apr 27, 2026 - FOLD was delisted (reason: acquired by BMRN)
14.49
0.00 (0.00%)
Inactive · Last trade price on Apr 24, 2026

Amicus Therapeutics Stock Forecast

Stock Price Forecast

The 9 analysts with 12-month price forecasts for Amicus Therapeutics stock had an average target of $27.25, with a low estimate of $11 and a high estimate of $108.

Price Target: $27.25 (+88.06%)
Analyst Consensus: Buy

Price Target

TargetLowAverageMedianHigh
Price$11$27.25n/a$108
Change-24.09%+88.06%n/a+645.34%

Analyst Ratings

The average analyst rating for Amicus Therapeutics stock from 9 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.

Recommendation Trends

No data available
RatingOct 2026
Strong Buyn/a
Buyn/a
Holdn/a
Selln/a
Strong Selln/a
Totaln/a

Financial Forecast

Revenue This Year
764.22M
from 634.21M
Increased by 20.50%
Revenue Next Year
906.32M
from 764.22M
Increased by 18.59%
EPS This Year
0.34
from -0.09
EPS Next Year
0.64
from 0.34
Increased by 86.82%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
305.51M329.23M399.36M528.30M634.21M764.22M906.32M
Revenue Growth
17.11%7.76%21.30%32.29%20.05%20.50%18.59%
EPS
-0.92-0.82-0.51-0.18-0.090.340.64
EPS Growth
------86.82%
Forward PE
-----42.4522.72
No. Analysts
-----1110

Revenue Forecast

Revenue20262027202820292030203120322033
High822.2M989.2M
Avg764.2M906.3M
Low721.2M829.1M

Revenue Growth

Revenue Growth20262027202820292030203120322033
High
29.6%
29.4%
Avg
20.5%
18.6%
Low
13.7%
8.5%

EPS Forecast

EPS20262027202820292030203120322033
High0.580.92
Avg0.340.64
Low0.240.30

EPS Growth

EPS Growth20262027202820292030203120322033
High-
170.7%
Avg-
86.8%
Low-
-11.0%